Table 3 Univariate and multivariate analyses of overall survival in high-expression of hsa-mir-3923 in patients with GC.
From: MicroRNA hsa-mir-3923 serves as a diagnostic and prognostic biomarker for gastric carcinoma
Parameters | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
Hazard ratio | 95% CI | P-value | Hazard ratio | 95% CI | P-value | |
Age, years (≤55 > 55) | 4.965 | 1.003–1.052 | 0.026 |  |  |  |
Gender (Female & Male) | 4.649 | 0.356–0.952 | 0.031 |  |  |  |
Race (Asian & Black & White) | 0.536 | 0.832–1.495 | 0.464 | 1.714 | 0.872–2.13 | 0.175 |
Grade (G1 & G2 & G3 & G4) | 0.365 | 0.727–1.827 | 0.546 | 1.121 | 0.724–2.952 | 0.29 |
Stage (Stage I & II & III & IV) | 1.478 | 0.769–2.501 | 0.078 | 1.796 | 1.14–2.122 | 0.005 |
T stage (T1 & T2 & T3 & T4) | 1.843 | 0.707–2.525 | 0.191 | 2.165 | 1.269–3.120 | 0.057 |
M stage (M0 & M1) | 0.016 | 0.31–3.795 | 0.898 |  |  |  |
N stage (N0 & N1/2/3) | 0.001 | 0.738–1.344 | 0.979 |  |  |  |
Hsa-mir-3923 | 0.332 | 0.561–1.371 | 0.564 |  |  |  |
